Friday, May 28, 2010

IMF Conference Call Previewing the Upcoming ASCO Meeting

A conference call, sponsored by the  International Myeloma Foundation, was held this morning to preview information to be presented at June's American Society of Clinical Oncology (ASCO) meeting in Chicago. The call was lead by Brian G. M. Durie, MD,Chairman and Medical Director of the International Myeloma Foundation and myeloma specialist at Cedars-Sinai Outpatient Cancer Center.

Some highlights of the call:

Dr. Durie briefly talked about what he referred to as the 'Three Muskateers of MM novel agents' - Thalidomide, Velcade and   Revlimid. He also mentioned new drugs in the pipeline -  most notably Carfilzomib, Cytoxin, Pomalidomide and other new agents being studied.

Two significant multi-national trials conducted by the French group, Inter Groupe Francophone du Myelome (IFM), and the American group, Cancer and Leukemia Group B (CALGB), regarding the use of Revlimid as a maintenance novel agent after induction and stem cell transplants were discussed.

Dr. Durie stated that there have been 'spectacular results' with the use of the three drug combination of Velcade, Revlimid and Dexamethasone in maintenance settings. He shared that Revlimid seems to be well tolerated in the longer term of use, citing that one of his patients has been using the novel agent for eight years with nominal side effects.

Among other highlights to be presented at ASCO, will be approximately 50 abstracts focusing on Velcade (bortezomib) and its expanding use in Myeloma treatment,  The Italian Multiple Myeloma Study Group's focus on molecular remission, the continued use of cytogenetics in treating MM,   and many other exciting presentations.  

Dr. Durie also said that the inaugural Summit of the International Myeloma Working Group will convene after the ASCO conference dismisses. 

For more detailed information please take a look at the ASCO meeting preview at The Myeloma Beacon's website at .   

Stay tuned for the latest & keep fighting!

1 comment:

Nick said...

Sean -

Hello from Little Rock!

I listened in to the Durie call which was quite interesting (and which of course validates more and more of BB's approach). I remember my original hematologist stating quite matter-of-factly a year ago: "I don't believe in maintenance therapy.". Hmm.

I also emailed in a question which was a teensy bit off topic but which Durie answered: evidently 80 percent of researchers feel that the immune system does recover a "memory" of previous immunities over the first year after transplant so no re-immunization is needed. That is good information for you and me! It would be wonderful for 100 percent to agree but then this is Myeloma so that's of course too much to ask. ;)

All the best to you and your family,

Your friend,